- Home
- MSB vs RIGL Comparison
MSB vs RIGL Comparison
Compare MSB & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSB
- RIGL
- Stock Information
- Founded
- MSB 1961
- RIGL 1996
- Country
- MSB United States
- RIGL United States
- Employees
- MSB N/A
- RIGL N/A
- Industry
- MSB Metal Mining
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- MSB Basic Materials
- RIGL Health Care
- Exchange
- MSB Nasdaq
- RIGL Nasdaq
- Market Cap
- MSB 351.7M
- RIGL 366.5M
- IPO Year
- MSB N/A
- RIGL 2000
- Fundamental
- Price
- MSB $26.82
- RIGL $18.21
- Analyst Decision
- MSB
- RIGL Buy
- Analyst Count
- MSB 0
- RIGL 5
- Target Price
- MSB N/A
- RIGL $36.80
- AVG Volume (30 Days)
- MSB 35.3K
- RIGL 232.8K
- Earning Date
- MSB 01-01-0001
- RIGL 03-04-2025
- Dividend Yield
- MSB 25.73%
- RIGL N/A
- EPS Growth
- MSB 714.88
- RIGL N/A
- EPS
- MSB 7.00
- RIGL 0.99
- Revenue
- MSB $26,785,162.00
- RIGL $179,278,000.00
- Revenue This Year
- MSB N/A
- RIGL $14.19
- Revenue Next Year
- MSB N/A
- RIGL $13.10
- P/E Ratio
- MSB $3.91
- RIGL $17.32
- Revenue Growth
- MSB 85.21
- RIGL 54.71
- 52 Week Low
- MSB $15.93
- RIGL $7.48
- 52 Week High
- MSB $37.00
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- MSB 48.77
- RIGL 41.05
- Support Level
- MSB $26.02
- RIGL $16.90
- Resistance Level
- MSB $27.77
- RIGL $19.97
- Average True Range (ATR)
- MSB 1.19
- RIGL 1.06
- MACD
- MSB 0.04
- RIGL -0.24
- Stochastic Oscillator
- MSB 41.96
- RIGL 30.54
About MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of the assets held. The company's principally wholly-owned segment is the iron ore mining segment and it generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.